ES3052874T3 - Composition comprising sodium hyaluronate and amino acids for use in the orthopedic field - Google Patents
Composition comprising sodium hyaluronate and amino acids for use in the orthopedic fieldInfo
- Publication number
- ES3052874T3 ES3052874T3 ES22789675T ES22789675T ES3052874T3 ES 3052874 T3 ES3052874 T3 ES 3052874T3 ES 22789675 T ES22789675 T ES 22789675T ES 22789675 T ES22789675 T ES 22789675T ES 3052874 T3 ES3052874 T3 ES 3052874T3
- Authority
- ES
- Spain
- Prior art keywords
- concentration
- composition according
- sodium hyaluronate
- molecular weight
- kda
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102021000023894A IT202100023894A1 (it) | 2021-09-16 | 2021-09-16 | Composizione per utilizzo in campo ortopedico |
| PCT/IB2022/058720 WO2023042120A1 (en) | 2021-09-16 | 2022-09-15 | Composition comprising sodium hyaluronate and am inoacids for use in the orthopedic filed |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3052874T3 true ES3052874T3 (en) | 2026-01-15 |
Family
ID=78771031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES22789675T Active ES3052874T3 (en) | 2021-09-16 | 2022-09-15 | Composition comprising sodium hyaluronate and amino acids for use in the orthopedic field |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240366653A1 (pl) |
| EP (1) | EP4401743B1 (pl) |
| KR (1) | KR20240063914A (pl) |
| CN (1) | CN117957004A (pl) |
| AU (1) | AU2022345524A1 (pl) |
| ES (1) | ES3052874T3 (pl) |
| HR (1) | HRP20251328T1 (pl) |
| IT (1) | IT202100023894A1 (pl) |
| PL (1) | PL4401743T3 (pl) |
| RS (1) | RS67349B1 (pl) |
| WO (1) | WO2023042120A1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU505892B1 (fr) * | 2023-12-21 | 2025-06-24 | Lumatrix | Formule pharmaceutique de cicatrisation et de régénération de la peau et son utilisation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20052515A1 (it) * | 2005-12-29 | 2007-06-30 | Abiogen Pharma Spa | Formulazione farmaceutica per il trattamento della osteoartrite |
| CA2910325A1 (en) * | 2013-04-25 | 2014-10-30 | Aluron Biopharma Inc. | Crosslinked hyaluronic acid compositions |
-
2021
- 2021-09-16 IT IT102021000023894A patent/IT202100023894A1/it unknown
-
2022
- 2022-09-15 KR KR1020247009798A patent/KR20240063914A/ko active Pending
- 2022-09-15 CN CN202280062464.8A patent/CN117957004A/zh active Pending
- 2022-09-15 AU AU2022345524A patent/AU2022345524A1/en active Pending
- 2022-09-15 US US18/691,052 patent/US20240366653A1/en active Pending
- 2022-09-15 ES ES22789675T patent/ES3052874T3/es active Active
- 2022-09-15 EP EP22789675.0A patent/EP4401743B1/en active Active
- 2022-09-15 HR HRP20251328TT patent/HRP20251328T1/hr unknown
- 2022-09-15 PL PL22789675.0T patent/PL4401743T3/pl unknown
- 2022-09-15 WO PCT/IB2022/058720 patent/WO2023042120A1/en not_active Ceased
- 2022-09-15 RS RS20251080A patent/RS67349B1/sr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022345524A1 (en) | 2024-02-15 |
| HRP20251328T1 (hr) | 2025-12-19 |
| IT202100023894A1 (it) | 2023-03-16 |
| EP4401743B1 (en) | 2025-09-03 |
| CN117957004A (zh) | 2024-04-30 |
| PL4401743T3 (pl) | 2025-12-15 |
| RS67349B1 (sr) | 2025-11-28 |
| EP4401743C0 (en) | 2025-09-03 |
| WO2023042120A1 (en) | 2023-03-23 |
| KR20240063914A (ko) | 2024-05-10 |
| US20240366653A1 (en) | 2024-11-07 |
| EP4401743A1 (en) | 2024-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Marzook et al. | Intra-articular injection of a mixture of hyaluronic acid and corticosteroid versus arthrocentesis in TMJ internal derangement | |
| Van Valburg et al. | Joint distraction in treatment of osteoarthritis: a two-year follow-up of the ankle | |
| EA011708B1 (ru) | Применение транс- капсаицина | |
| JP2011105741A (ja) | 骨関節症を治療するための、ヒアルロン酸ナトリウムとコンドロイチン硫酸との混合物の使用 | |
| ES2317018T3 (es) | Procedimiento para el tratamiento de un esguince y una distension agudos o debidos a una utilizacion excesiva utilizando acido hialuronico. | |
| Petrella et al. | Long-term efficacy and safety of periarticular hyaluronic acid in acute ankle sprain | |
| Razzano et al. | Noninvasive interactive neurostimulation therapy for the treatment of low-grade lateral ankle sprain in the professional contact sport athlete improves the short-term recovery and return to sport: a randomized controlled trial | |
| ES3052874T3 (en) | Composition comprising sodium hyaluronate and amino acids for use in the orthopedic field | |
| RU2268052C2 (ru) | Средство для лечения воспалительных и дегенеративных заболеваний суставов (варианты), способ лечения воспалительных и дегенеративных заболеваний суставов (варианты) и устройство для доставки лекарственного средства к пораженному участку | |
| US20160106774A1 (en) | Liquid pharmaceutical composition containing piroxicam and hyaluronic acid for the treatment of osteoarthritis | |
| KR20220152904A (ko) | Dna 분획물 및 콘드로이틴 설페이트를 포함하는 관절염 예방 또는 치료용 조성물 | |
| ES2447829T3 (es) | Combinación para el tratamiento de la osteoartritis | |
| Yu et al. | Creatine derivatives: rapid complete relief of pain by topical or transcutaneous administration | |
| CN110711244B (zh) | 一种神经导向因子Sema在制备治疗骨关节炎搽剂中的应用 | |
| HK40109892A (zh) | 用於整形外科领域的包含透明质酸钠和氨基酸的组合物 | |
| Dohnert et al. | High frequency transcutaneous electrical stimulation in the immediate postoperative period of anterior cruciate ligament reconstruction: a randomized clinical trial | |
| RU2350366C1 (ru) | Способ лечения последствий травм суставов | |
| Lynen | Treatment of chronic tendinopathies with peritendinous hyaluronan injections under sonographic guidance—An interventional, prospective, single-arm, multicenter study | |
| US11642328B2 (en) | Creatine, its derivatives, compositions and methods of use thereof | |
| EP3687550A1 (en) | New therapy for osteoarthritic pain | |
| US11654185B2 (en) | Use of hyaluronidase for treatment of muscle stiffness | |
| Dohnert et al. | Received: Feb 04, 2021 Revised: Apr 21, 2021 Approved: Jun 05, 2021 | |
| WO2022157181A1 (en) | Use of link-tsg6 for the treatment of osteoarthritic pain | |
| Milani | The collagen Medical Devices in the local treatment of the algic arthro-rheumopathies | |
| RU2436584C1 (ru) | Способ лечения дегеративно-дистрофических заболеваний опорно-двигательного аппарата и посттравматических спаечных процессов |